Back to Search
Start Over
First Trimester CD93 as a Novel Marker of Preeclampsia and Its Complications: A Pilot Study.
- Source :
-
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension [High Blood Press Cardiovasc Prev] 2023 Nov; Vol. 30 (6), pp. 591-594. Date of Electronic Publication: 2023 Nov 27. - Publication Year :
- 2023
-
Abstract
- Introduction: CD93 plays a crucial role in endothelial homeostasis and angiogenesis. Recently its role in hypertension has been investigated, holding promise for novel targeted diagnostic and therapeutic strategies.<br />Aim: We assessed for the first time differences in first trimester serum CD93 levels in women who lately developed preeclampsia (PE) vs. normotensive pregnancy (NP).<br />Methods: First trimester serum CD93 concentrations were assessed in a multicenter cohort of 83 women (34 PE and 49 NP) by ELISA Immunoassay.<br />Results: Serum CD93 was lower in women who developed PE vs. NP (111.8 ± 24.4 vs. 137.5 ± 22.3 ng/ml; p < 0.001). Serum CD93 was associated with a decreased risk of developing PE (OR 0.950, 95% CI 0.922-0.978) and composite neonatal outcome (OR 0.952, CI 0.923-0.982), after adjustment for confounders.<br />Conclusions: PE is accompanied by decreased serum CD93 levels. CD93 might play a role during placentation leading to defective angiogenesis, vascular dysfunction, and PE development.<br /> (© 2023. Italian Society of Hypertension.)
Details
- Language :
- English
- ISSN :
- 1179-1985
- Volume :
- 30
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
- Publication Type :
- Academic Journal
- Accession number :
- 38010536
- Full Text :
- https://doi.org/10.1007/s40292-023-00608-y